Hemab Therapeutics Holdings COAG
NASDAQ COAG
$40.86 +1.48 (+3.76%)
At close: Nov 13, 2026 · 4:00 PM EST

Hemab Therapeutics Holdings (COAG) Preferred Stock Liabilities (2025)

Updated

Hemab Therapeutics Holdings (COAG) recorded Preferred Stock Liabilities of $360.17 million in Q4 2025.

Analysis

Hemab Therapeutics Holdings (COAG) Preferred Stock Liabilities (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn -
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn -
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn -
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn -
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn -
10 Hemab Therapeutics Holdings 1.91 Bn 672.70 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 360.17 Mn
API Access

Hemab Therapeutics Holdings Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=COAG&period=max&api_key=YOUR_API_KEY